Skip to main content
SpringerLink
Log in

Heart Transplantation

  • Chapter
Surgery

  • 782 Accesses

Abstract

The clinical success of cardiac transplantation for patients suffering from end-stage heart failure has led to an increased demand for heart donors. Currently, one-third of patients listed for transplantation die while awaiting a suitable donor organ. The availability of donor organs is presently the primary limiting factor to cardiac transplantation. As in the case of abdominal organs, a common approach has been to extend the acceptance criteria for hearts. Donor parameters such as advanced age, high-dose inotropic support, seropositivity for hepatitis C, size mismatch, echocardiographic abnormality, and prolonged cold ischemic time have been reconsidered as contraindications to organ usage. Certain criteria such as donor seropositivity for HIV, intractable ventricular dysrhythmias, extracranial malignancy, documented prior myocardial infarction, severe coronary artery or valvular disease, and death from carbon monoxide poisoning with a blood carboxyhemoglobin level greater than 20% remain absolute contraindications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hosenpud JD, Novick RJ, Breen TJ, et al. The registry of the International Society for Heart and Lung Transplantation: eleventh official report-1994. J Heart Lung Transplant 1994; 13: 561–570.

    PubMed  CAS  Google Scholar 

  2. Breen TJ, Keck B, Daily P, et al. The use of older donors results in a major increase in early mortality following orthotopic cardiac transplantation. J Heart Lung Transplant 1994; 13: S51.

    Google Scholar 

  3. Livi U; Bortolotti U, Luciani GB, et al. Donor shortage in heart transplantation: is extension of donor age limits justified? J Tho-rac Cardiovasc Surg 1994; 107: 1346–1355.

    CAS  Google Scholar 

  4. Chau EMC, McGregor CGA, Rodeheffer JR, et al. Increased incidence of chronotropic incompetence in older donor hearts. J Heart Lung Transplant 1995; 14: 743–748.

    PubMed  CAS  Google Scholar 

  5. Mercer P, Sharpies L, Edmunds J, et al. Evaluating the donor pool: impact of using hearts from donors over the age of 49 years. Transplant Proc 1997; 29: 3293–3296.

    PubMed  CAS  Google Scholar 

  6. Gao, S-Z, Hunt SA, Alderman EL, et al. Relation of donor age and preexisting coronary artery disease on angiography and in-tracoronary ultrasound to later development of accelerated allograft coronary artery disease. J Am Coll Cardiol 1997; 29: 623–629.

    PubMed  CAS  Google Scholar 

  7. Lim HL, Lau GK, Davis GL, et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitic C virus infection. Gastroenterology 1994; 106: 248–251.

    PubMed  CAS  Google Scholar 

  8. Lake KD, Smith CI, Laforest SKM, et al. Policies regarding the transplantation of hepatitis C-positive candidates and donor organs. J Heart Lung Transplant 1997; 16: 917–921.

    PubMed  CAS  Google Scholar 

  9. Widell A, Mansson S, Persson NH, et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation (Baltimore) 1995; 60: 642–647.

    CAS  Google Scholar 

  10. Chan BB, Fleischer KJ, Bergin JD, et al. Weight is not an accurate criterion for adult cardiac transplant size. Ann Thorac Surg 1991; 52: 1230–1235.

    PubMed  CAS  Google Scholar 

  11. Hosenpud JD, Pantely GA, Morton MJ, et al. Relation between recipient: donor body size match and hemodynamics three months after heart transplantation. J Heart Transplant 1989; 8: 241–243.

    PubMed  CAS  Google Scholar 

  12. Jeevanandam V, Mather P, Furukawa S, et al. Adult orthotopic heart transplantation using undersized pediatric donor hearts. Circulation 1994; 90 (partII): 1174–1177.

    Google Scholar 

  13. Sekela ME, Smart FW, Noon GP, et al. Attenuation of waiting time mortality with heterotopic heart transplantation. Ann Thorac Surg 1992; 54: 547–551.

    PubMed  CAS  Google Scholar 

  14. Tamisier D, Vouhe P, Le Bidois J, et al. Donor-recipient size matching in pediatric heart transplantation: a word of caution about small grafts. J Heart Lung Transplant 1996; 15: 190–195.

    PubMed  CAS  Google Scholar 

  15. Iberer F, Wasler A, Tscheliessnigg K, et al. Prostaglandin Ei-induced moderation of elevated pulmonary vascular resistance: survival on waiting list and results of orthotopic heart transplantation. J Heart Lung Transplant 1993; 12: 173–178.

    PubMed  CAS  Google Scholar 

  16. Sharpies LD, Caine N, Mullins P, et al. Risk factor analysis for the major hazards following heart transplantation-rejection, infection, and coronary occlusive disease. Transplantation 1991; 52: 244–252.

    Google Scholar 

  17. Mehra MR, Stapleton DD, Ventura HO, et al. Influence of donor and recipient gender on cardiac allograft vasculopathy: an intravascular ultrasound study. Circulation 1994; 90 (part 2): 1178–1182.

    Google Scholar 

  18. Kirsh M, Baufreton C, Naftel DC, et al. Pretransplantation risk factors for death after heart transplantation: the Henri Mondor experience. J Heart Lung Transplant 1998; 17: 268–277.

    Google Scholar 

  19. Prendergast TW, Furukawa S, Beyer AJ III, et al. The role of gender in heart transplantation. Ann Thorac Surg 1998; 65: 88–94.

    PubMed  CAS  Google Scholar 

  20. Jeevanandam V, Todd B, Regillo T, et al. Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy. J Heart Lung Transplant 1994; 13: 681–687.

    PubMed  CAS  Google Scholar 

  21. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid 1997; 7: 139–145.

    PubMed  CAS  Google Scholar 

  22. Wheeldon DR, Potter CD, Jonas M, et al. Transplantation of “unsuitable” organs? Transplant Proc 1993; 25: 3104–3105.

    PubMed  CAS  Google Scholar 

  23. Stein JH, Neumann A, Preston LM, et al. Echocardiography for hemodynamic assessment of patients with advanced heart failure and potential heart transplant recipients. J Am Coll Cardiol 1997; 30: 1765–1772.

    PubMed  CAS  Google Scholar 

  24. Adatia I, Perry S, Landzberg M, et al. Inhaled nitric oxide and hemodynamic evaluations of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol 1995; 25: 1565–1564.

    Google Scholar 

  25. Chen JM, Levin HR, Michler RE, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 1997; 114: 627–634.

    PubMed  CAS  Google Scholar 

  26. Michler RE, Chen JM, Itescu S, et al. Two decades of cardiac transplantation at the Columbia-Presbyterian Medical Center: 1977–1997. Clin Transpl 1996; 153–165.

    Google Scholar 

  27. Kirsch M, Baufreton C, Naftel D, et al. Pretransplantation risk factors for death after heart transplantation: the Henri Mondor experience. J Heart Lung Transplant 1998; 17: 268–277.

    PubMed  CAS  Google Scholar 

  28. McCarthy JF, McCarthy PM, Massad MG, et al. Risk factors for death after heart transplantation: does a single-center experience correlate with multicenter registries? Ann Thorac Surg 1998; 65: 1574–1579.

    PubMed  CAS  Google Scholar 

  29. Tenderich G, Koerner MM, Stuettgen L, et al. Does preexisting elevated pulmonary vascular resistance (transpulmonary gradient < 15 mm Hg or < 5 Wood) predict early and long-term results after orthotopic heart transplantation? Transplant Proc 1998; 30: 1130–1131.

    PubMed  CAS  Google Scholar 

  30. Ladowski JS, Kormos RL, Uretsky BF, et al. Heart transplantation in diabetic recipients. Transplantation 1990; 49: 303–305.

    PubMed  CAS  Google Scholar 

  31. Munoz E, Lonquist JL, Radovancevic B, et al. Long-term results in diabetic patients undergoing heart transplantation. J Heart Lung Transplant 1992; 11: 943–949.

    PubMed  CAS  Google Scholar 

  32. Stevenson LW, Warner SL, Steimle AE, et al. The impending crisis awaiting cardiac transplantation: modeling a solution based on selection. Circulation 1994; 89: 450–457.

    PubMed  CAS  Google Scholar 

  33. Laics H, Scholl GF, Drinkwater DC, et al. The alternate recipient list for heart transplantation: does it work? J Heart Lung Transplant 1997; 16: 735–742.

    Google Scholar 

  34. Anguita M, Arizon JM, Vallès F, et al. Influence on survival after heart transplantation of contraindications seen in transplant recipients. J Heart Lung Transplant 1992; 11: 708–715.

    PubMed  CAS  Google Scholar 

  35. Miller LW, Rubo SH, Young JB, et al. Report of the consensus conference on candidate selection for heart transplantation-1993. J Heart Lung Transplant 1995; 14: 562–571.

    PubMed  CAS  Google Scholar 

  36. Blanche C, Matloff JM, Denton TA, et al. Heart transplantation in patients 70 years of age and older: initial experience. Ann Thorac Surg 1996; 62: 1731–1736.

    PubMed  CAS  Google Scholar 

  37. Frazier OH, Macris MP, Duncan JM, et al. Cardiac transplantation in patients over 60 years of age. Ann Thorac Surg 1997; 64: 1866–1867.

    PubMed  CAS  Google Scholar 

  38. Masters RG, Hendry PJ, Davies RA, et al. Cardiac transplantation after mechanical circulatory support: a Canadian perspective. Ann Thorac Surg 1996; 61: 1734–1739.

    PubMed  CAS  Google Scholar 

  39. Arzenziano M, Catanese KA, Moazami N, et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 1997; 16: 822–831.

    Google Scholar 

  40. Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98: 786–793.

    PubMed  CAS  Google Scholar 

  41. Cavarocchi NC; Badellino M. Heart/heart-lung transplantation: the domino procedure. Ann Thorac Surg 1989; 48: 130–133.

    PubMed  CAS  Google Scholar 

  42. Traversi E, Pozzoli M, Grande A. The bicaval anastomosis technique for orthotopic heart transplantation yields better atrial function than the standard technique: an echocardiographic automatic boundary detection study. J Heart Lung Transplant 1998; 17: 1065–1074.

    PubMed  CAS  Google Scholar 

  43. Blanche C, Nessim S, Quartel A, et al. Heart transplantation with bicaval and pulmonary venous anastomoses. A hemodynamic analysis of the first 117 patients. J Cardiovasc Surg 1997; 38: 561–566.

    CAS  Google Scholar 

  44. Brandt M, Harringer W, Hirt SW, et al. Influence of bicaval anastomoses on late occurrence of atrial arrhythmia after heart transplantation. Ann Thorac Surg 1997; 64: 70–72.

    PubMed  CAS  Google Scholar 

  45. Rothman SA, Jeevanandam V, Combs WG, et al. Eliminating bradyarrhythmias after orthotopic heart transplantation. Circulation 1996; (suppl 9 ): 11178–11182.

    Google Scholar 

  46. Bouchart F, Derumeaux G, Mouton-Schleifer D, et al. Conventional and total orthotopic cardiac transplantation: a comparative clinical and echocardiographical study. Eur J Cardiothorac Surg 1997; 12: 555–559.

    PubMed  CAS  Google Scholar 

  47. Aleksic I, Freimark D, Blanche C, et al. Resting hemodynamics after total versus standard orthotopic heart transplantation in patients with high preoperative pulmonary vascular resistance. Eur J Cardiothorac Surg 1997; 11: 1037–1044.

    PubMed  CAS  Google Scholar 

  48. Deleuze PH, Benvenuti C, Mazzucotelli JP, et al. Orthotopic cardiac transplantation with direct cavai anastomosis: is it the optimal procedure? J Thorac Cardiovasc Surg 1995; 109: 731–737.

    PubMed  CAS  Google Scholar 

  49. elGamel A, Yonan NA, Grant S, et al. Orthotopic cardiac transplantation: a comparison of standard and bicaval Wythenshawe techniques. J Thorac Cardiovasc Surg 1995; 109: 721–730.

    CAS  Google Scholar 

  50. Sievers HH, Leyh R, Jahnke A, et al. Bicaval versus atrial anastomoses in cardiac transplantation: right atrial dimension and tricuspid valve function at rest and during exercise up to thirty-six months after transplantation. J Thorac Cardiovasc Surg 1995; 109: 1257–1259.

    Google Scholar 

  51. Wheeldon D, Sharpies L, Wallwork J, et al. Donor heart preservation survey. J Heart Lung Transplant 1992; 11: 986–993.

    PubMed  CAS  Google Scholar 

  52. Luciani GB, Faggian G, Forni A, et al. Myocardial protection during heart transplantation using blood cardioplegia. Transplant Proc 1997; 29: 3386–3388.

    PubMed  CAS  Google Scholar 

  53. Engelman RM, Pleet AB, Rousou JA, et al. What is the best perfusion temperature for coronary revascularization? J Thorac Cardiovasc Surg 1996; 112: 1622–1633.

    PubMed  CAS  Google Scholar 

  54. Tixier D, Matheis G, Buckberg GD, et al. Donor hearts with impaired hemodynamics. J Thorac Cardiovasc Surg 1991; 102: 207–214.

    PubMed  CAS  Google Scholar 

  55. Rao V, Feindel CM, Weisel RD, et al. Donor blood perfusion improves myocardial recovery after heart transplantation. J Heart Lung Transplant 1997; 16: 667–673.

    PubMed  CAS  Google Scholar 

  56. Kirklin JK, Neves J, Naftel DC, et al. Controlled initial hyper-kalemic reperfusion after cardiac transplantation: coronary vascular resistance and blood flow. Ann Thorac Surg 1990; 49: 625–631.

    PubMed  CAS  Google Scholar 

  57. Pradas G, Cuenca J, Juffé A. Continuous warm reperfusion during heart transplantation. J Thorac Cardiovasc Surg 1996; 111: 784–790.

    PubMed  CAS  Google Scholar 

  58. Barnard CN, Losman JG. Left ventricular bypass. South African Med J 1975; 49: 303–312.

    CAS  Google Scholar 

  59. Cooper DK, Novitzlcy D, Becerra E, et al. Are there indications for heterotopic heart transplantation in 1986? A 2- to 11-year follow-up of 49 consecutive patients undergoing heterotopic heart transplantation. Thor Cardiovasc Surgeon 1986; 34: 300–304.

    CAS  Google Scholar 

  60. Baumgartner WA. Heterotopic transplantation: is it a viable alternative? Ann Thorac Surg 1992; 54: 401–402.

    PubMed  CAS  Google Scholar 

  61. Kawaguchi AT, Gandjbakhch I, Desruennes M, et al. Orthotopic vs heterotopic heart transplantation in donor/recipient size mismatch. Transplant Proc 1995; 27: 1227–1281.

    Google Scholar 

  62. Khaghani A, Santini F, Dyke CM, et al. Heterotopic cardiac transplantation in infants and children. J Thorac Cardiovasc Surg 1997; 113: 1042–1049.

    PubMed  CAS  Google Scholar 

  63. Ridley PD, Khaghani A, Musumeci F, et al. Heterotopic heart transplantation and recipient heart operation in ischemic heart disease. Ann Thorac Surg 1992; 54: 333–337.

    PubMed  CAS  Google Scholar 

  64. Chester AH, Birks EJ, Yacoub MH. Role of nitric oxide following cardiac transplantation. J Hum Hypertens 1998; 12: 883–887.

    Google Scholar 

  65. Argenziano M, Chen JM, Choudri AF, et al. Management of va-sodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116: 973–980.

    PubMed  CAS  Google Scholar 

  66. Montero JA, Anguita M, Concha M, et al. Pacing requirements after orthotopic heart transplantation: incidence and related factors. J Heart Lung Transplant 1992; 11: 799–802.

    PubMed  CAS  Google Scholar 

  67. Scott CD, McComb JM, Dark JH, et al. Permanent pacing after cardiac transplantation. Br Heart J 1993; 399–403.

    Google Scholar 

  68. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin El, and sodium nitroprusside. J Heart Lung Transplant 1995; 14: 436–443.

    PubMed  CAS  Google Scholar 

  69. Auler JOC, Carmona MJC, Bocchi EA, et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant 1996; 15: 443–450.

    Google Scholar 

  70. Valantine HA. Individualizing immunosuppression for heart transplantation: strategies for the next decade. Transplant Proc 1999; 29 (suppl 8A): 5S - 8S.

    Google Scholar 

  71. Waid TH, Johnson JS, McKeown JW, et al. Induction immunotherapy in heart transplantation with T10B3. 1A-31: a phase I study. J Heart Lung Transplant 1997; 16: 913–916.

    PubMed  CAS  Google Scholar 

  72. vanGelder T, Balk AH, Jonkman FA, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996; 62: 51–55.

    CAS  Google Scholar 

  73. Wahlers T. Cytolytic induction therapy in heart and lung transplantation: the protagonist opinion. Transplant Proc 1998; 30: 1100–1103.

    PubMed  CAS  Google Scholar 

  74. Keogh A, Macdonald PO, Harvison A, et al. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: two views of the steroid question. J Heart Lung Transplant 1992; 11: 421–427.

    PubMed  CAS  Google Scholar 

  75. Barr ML, Sanchez JA, Seche LA, et al. Anti-CD3 monoclonal antibody induction therapy: immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990; 82(suppl 5):IV291–IV294.

    PubMed  CAS  Google Scholar 

  76. Alonso-Pulpön L, Serrano-Fiz S, Rubio JA, et al. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation. J Heart Lung Transplant 1995; 14: 136–142.

    PubMed  Google Scholar 

  77. Costanzo-Nordin MR, Sinnen LJ, Fisher SG, et al. Cytomegalovirus infections in heart transplant recipients: relationship to immunosuppression. J Heart Lung Transplant 1992; 11: 837–846.

    PubMed  CAS  Google Scholar 

  78. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723–1728.

    PubMed  CAS  Google Scholar 

  79. Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–232.

    PubMed  CAS  Google Scholar 

  80. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant. Transplantation 1993; 56: 75–82.

    PubMed  CAS  Google Scholar 

  81. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507–515.

    PubMed  CAS  Google Scholar 

  82. Haverich A, Costard-Jäckle A, Cremer J, et al. Cyclosporin A and transplant coronary disease after heart transplantation. Transplant Proc 1994; 26: 2713–2715.

    PubMed  CAS  Google Scholar 

  83. Stempfle HU, Werner C, Echtler S, et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc 1998; 30: 1132–1133.

    PubMed  CAS  Google Scholar 

  84. Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17: 782–788.

    PubMed  CAS  Google Scholar 

  85. Reichart B, Meisr B, Vigano M, et al. European multicenter tacrolimus (FK506) heart pilot study: one-year-results-European tacrolimus multicenter heart study group. J Heart Lung Transplant 1998; 17: 775–781.

    PubMed  CAS  Google Scholar 

  86. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermedi-ate-term results. J Thorac Cardiovasc Surg 1996; 111: 764–772.

    PubMed  CAS  Google Scholar 

  87. Olivari MT, Jesse ME, Baldwin BJ, et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 1995; 14: 127–135.

    PubMed  CAS  Google Scholar 

  88. Kobashigawa JA, Stevenson LW, Brownfield ED, et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 1992; 11: 428–430.

    PubMed  CAS  Google Scholar 

  89. Miller LW, McBride WT, Peigh P, et al. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 1992; 11: 431–434.

    PubMed  CAS  Google Scholar 

  90. Canter CEW, Moorhead S, Saffitz JE, et al. Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression. J Heart Lung Transplant 1994; 13: 74–80.

    PubMed  CAS  Google Scholar 

  91. White JA, Guiraudon C, Pflugfelder PW, et al. Routine surveillance myocardial biopsies are unnecessary beyond one year after heart transplantation. J Heart Lung Transplant 1995; 14: 1052–1056.

    PubMed  CAS  Google Scholar 

  92. Sethi GK, Kosaraju S, Arabia FA, et al. Is it necessary to perform surveillance endomyocardial biopsies in heart transplant recipients? J Heart Lung Transplant 1995; 14: 1047–1051.

    PubMed  CAS  Google Scholar 

  93. Brunner-La Rocca HP, Kiowski W. Identification of patients not requiring endomyocardial biopsies late after cardiac transplantation. Transplantation 1998; 65: 533–538.

    Google Scholar 

  94. Kobashigawa JA, Stevenson LW, Moriguchi J, et al. Randomized study of high dose oral cyclosporine therapy for mild acute cardiac rejection. J Heart Lung Transplant 1989; 8: 53–58.

    CAS  Google Scholar 

  95. Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. J Am Coll Cardiol 1993; 21: 1142–1144.

    PubMed  CAS  Google Scholar 

  96. Bourge RC, Kirklin JK, White-Williams C, et al. Methotrexate pulse therapy in the treatment of recurrent acute heart rejection. J Heart Lung Transplant 1992; 11: 1116–1124.

    PubMed  CAS  Google Scholar 

  97. Costanzo MR, Koch DM, Fisher SG, et al. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 1997; 16: 169–178.

    PubMed  CAS  Google Scholar 

  98. Kirklin JK, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994; 13: 444–450.

    PubMed  CAS  Google Scholar 

  99. Haverty TP, Sanders M, Sheahan M. OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant 1993; 12: 591–598.

    PubMed  CAS  Google Scholar 

  100. Wagner FM, Reichenspurner H, Überfuhr P, et al. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? J Heart Lung Transplant 1994; 13: 438–443.

    PubMed  CAS  Google Scholar 

  101. Dall II, Amico R, Livi U, Milano A, et al. Extracorporeal pho-tochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation 1995; 60: 45–49.

    Google Scholar 

  102. Costanzo-Nordin MR, Hubbell EA, O’Sullivan EJ, et al. Pho-tophoresis versus corticosteroids in the therapy of heart transplant rejection: preliminary clinical report. Circulation 1992; 86 (suppl 5): 11242–11250.

    Google Scholar 

  103. Costanzo-Nordin MR, Hubbell EA, O’Sullivan EJ, et al. Successful treatment of heart transplant rejection with photo-phoresis. Transplantation 1992; 53: 808–815.

    PubMed  CAS  Google Scholar 

  104. Rose EA, Barr ML, Xu H, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant 1992; 11: 746–759.

    PubMed  CAS  Google Scholar 

  105. Barr ML, Meisser BM, Eisen HJ, et al. Photophoresis for the prevention of rejection in cardiac transplantation: photophoresis transplantation study group. N Engl J Med 1998; 339: 1744–1751.

    PubMed  CAS  Google Scholar 

  106. Ross HJ, Gullestad L, Pale J, et al. Methotrexate of total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. J Heart Lung Transplant 1997; 16: 179–189.

    PubMed  CAS  Google Scholar 

  107. Grossi P, De Maria R, Caroli A, et al. Infections on heart transplant recipients: the experience of the Italian heart transplantation program. J Heart Lung Transplant 1992; 11: 847–866.

    PubMed  CAS  Google Scholar 

  108. Mayer JM, Nimer L, Carroll K. Isolated pulmonary aspergillus infection in cardiac transplant recipients: case report and review. Clin Infect Dis 1992; 15: 698–700.

    PubMed  CAS  Google Scholar 

  109. Munoz P, Palomo J, Munoz R, et al. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21: 398–402.

    PubMed  CAS  Google Scholar 

  110. Holliman RE, Johnson JD, Adams S, et al. Toxoplasmosis and heart transplantation. J Heart Transplant 1991; 10: 608–610.

    CAS  Google Scholar 

  111. Hutter JA, Scott J, Wreghitt T, et al. The importance of cytomegalovirus in heart-lung transplant recipients. Chest 1989; 95: 627–631.

    PubMed  CAS  Google Scholar 

  112. Griffiths PD. Prophylaxis against CMV infection in transplant patients. J Antimicrobial Chemotherapy 1997; 39: 299–301.

    CAS  Google Scholar 

  113. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182–1186.

    PubMed  CAS  Google Scholar 

  114. Kofoed KF, Czernin J, Johnson J, et al. Effects of cardiac allograft vasculopathy on myocardial blood flow, vasodilatory capacity, and coronary vasomotion. Circulation 1997; 95: 600–606.

    PubMed  CAS  Google Scholar 

  115. Libby P, Tanaka H. The pathogenesis of coronary arteriosclerosis (“chronic rejection”) in transplanted hearts. Clin Transplant 1994; 8: 313–318.

    PubMed  CAS  Google Scholar 

  116. Thomson JG. Production of severe athero in a transplanted human heart. Lancet 1969; 2: 1088–1092.

    PubMed  CAS  Google Scholar 

  117. Costanzo-Nordin MR. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992; 11: S90 - S103.

    PubMed  CAS  Google Scholar 

  118. Uretsky BF, Murali S, Reddy S, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827–834.

    PubMed  CAS  Google Scholar 

  119. Olivari MT, Homans DC, Wilson RF, et al. Coronary artery disease in cardiac transplant patients receiving triple drug immunosuppressive therapy. Circulation 1989; 80: 111111–111115.

    Google Scholar 

  120. Russell PS, Chase CM, Winn HF, et al. Coronary atherosclerosis in transplanted mouse hearts, II: importance of humoral immunity. J Immunol 1994; 152: 5135–5141.

    PubMed  CAS  Google Scholar 

  121. Hosenpud JD, Everett JP, Morris TE, et al. Cellular and humoral immunity to vascular endothelium and the development of cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14: S185 - S187.

    PubMed  CAS  Google Scholar 

  122. Escobar A, Ventura HO, Stapleton DD, et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994; 74: 1042–1046.

    PubMed  CAS  Google Scholar 

  123. Day JD, Rayburn BK, Gaudin PB, et al. Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995; 14:S142- S149.

    PubMed  CAS  Google Scholar 

  124. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994; 57: 211–217.

    PubMed  CAS  Google Scholar 

  125. Smith JA, Ribakove GH, Hunt SA, et al. Heart retransplantation: the 25-year experience at a single institution. J Heart Lung Transplant 1995; 14: 832–839.

    PubMed  CAS  Google Scholar 

  126. Schnetzler B, Pavie A, Dorent R, et al. Heart retransplantation: a 23-year single-center clinical experience. Ann Thorac Surg 1998; 65: 978–983.

    PubMed  CAS  Google Scholar 

  127. Mullins P, Scott J, Chauhan A, et al. Acute heart retransplantation. Lancet 1991; 337: 1158.

    Google Scholar 

  128. Collins EG, Mozdzierz G. Cardiac retransplantation: determining limits. Heart Lung 1993; 22: 206–212.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Daniel Kreisel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce R. Rosengard
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, San Francisco, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  2. Surgical Service, San Francisco VA Medical Center, San Francisco, California, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  3. Division of General Surgery, Duke University Medical Center, Durham, North Carolina, USA

    R. Randal Bollinger MD, PhD (Professor of Surgery, Professor of Immunology, Chief) (Professor of Surgery, Professor of Immunology, Chief)

  4. Division of Surgical Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, USA

    Alfred E. Chang MD (Chief, Hugh Cabot Professor of Surgery) (Chief, Hugh Cabot Professor of Surgery)

  5. Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    Stephen F. Lowry MD (Professor and Chairman) (Professor and Chairman)

  6. Division of General Surgery, University of California, San Francisco, San Francisco, California, USA

    Sean J. Mulvihill MD (Professor of Surgery, Chief) (Professor of Surgery, Chief)

  7. Karmanos Cancer Institute, Wayne State University, Harper Hospital, Detroit, Michigan, USA

    Harvey I. Pass MD (Professor of Surgery and Oncology, Chief of Thoracic Oncology) (Professor of Surgery and Oncology, Chief of Thoracic Oncology)

  8. Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA

    Robert W. Thompson MD (Associate Professor of Surgery) (Associate Professor of Surgery)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kreisel, D., Rosengard, B.R. (2001). Heart Transplantation. In: Norton, J.A., et al. Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57282-1_69

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57282-1_69

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63239-6

  • Online ISBN: 978-3-642-57282-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation